Overview

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Status:
Completed
Trial end date:
2018-07-09
Target enrollment:
Participant gender:
Summary
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Ustekinumab